202 related articles for article (PubMed ID: 31809940)
1. In vitro bactericidal activity of 3-cinnamoyl-4-hydroxy-6-methyl-2-pyrone (CHP) against drug-susceptible, drug-resistant and drug-tolerant isolates of Mycobacterium tuberculosis.
Bhat ZS; Rather MA; Ul Lah H; Hussain A; Maqbool M; Yousuf SK; Jabeen Z; Wani MA; Ahmad Z
J Glob Antimicrob Resist; 2020 Sep; 22():57-62. PubMed ID: 31809940
[TBL] [Abstract][Full Text] [Related]
2. In vitro potency of 2-(((2-hydroxyphenyl)amino)methylene)-5,5-dimethylcyclohexane-1,3-dione against drug-resistant and non-replicating persisters of Mycobacterium tuberculosis.
Rather MA; Bhat ZS; Lone AM; Maqbool M; Bhat BA; Ahmad Z
J Glob Antimicrob Resist; 2021 Jun; 25():202-208. PubMed ID: 33789204
[TBL] [Abstract][Full Text] [Related]
3. In vitro evaluation of dinactin, a potent microbial metabolite against Mycobacterium tuberculosis.
Hussain A; Rather MA; Bhat ZS; Majeed A; Maqbool M; Shah AM; Aga MA; Shah A; Mushtaq S; Sangwan PL; Hassan QP; Ahmad Z
Int J Antimicrob Agents; 2019 Jan; 53(1):49-53. PubMed ID: 30267759
[TBL] [Abstract][Full Text] [Related]
4. Interactions of linezolid and second-line anti-tuberculosis agents against multidrug-resistant Mycobacterium tuberculosis in vitro and in vivo.
Zhao W; Zheng M; Wang B; Mu X; Li P; Fu L; Liu S; Guo Z
Int J Infect Dis; 2016 Nov; 52():23-28. PubMed ID: 27613365
[TBL] [Abstract][Full Text] [Related]
5. In vitro interaction profiles of the new antitubercular drugs bedaquiline and delamanid with moxifloxacin against clinical Mycobacterium tuberculosis isolates.
Chandramohan Y; Padmanaban V; Bethunaickan R; Tripathy S; Swaminathan S; Ranganathan UD
J Glob Antimicrob Resist; 2019 Dec; 19():348-353. PubMed ID: 31226332
[TBL] [Abstract][Full Text] [Related]
6. Activity of rifampicin and linezolid combination in Mycobacterium tuberculosis.
Maltempe FG; Caleffi-Ferracioli KR; do Amaral RCR; de Oliveira Demitto F; Siqueira VLD; de Lima Scodro RB; Hirata MH; Pavan FR; Cardoso RF
Tuberculosis (Edinb); 2017 May; 104():24-29. PubMed ID: 28454646
[TBL] [Abstract][Full Text] [Related]
7. Determination of minimum bactericidal concentration, in single or combination drugs, against
Santos NCS; Scodro RBL; Leal DC; do Prado SM; Micheletti DF; Sampiron EG; Costacurta GF; de Almeida AL; da Silva LA; Ieque AL; Ghiraldi Lopes LD; de Pádua RA; Siqueira VL; Caleffi-Ferracioli KR; Cardoso RF
Future Microbiol; 2020 Jan; 15():107-114. PubMed ID: 32064924
[No Abstract] [Full Text] [Related]
8. In vitro effect of three-drug combinations of antituberculous agents against multidrug-resistant Mycobacterium tuberculosis isolates.
Rey-Jurado E; Tudó G; de la Bellacasa JP; Espasa M; González-Martín J
Int J Antimicrob Agents; 2013 Mar; 41(3):278-80. PubMed ID: 23312604
[TBL] [Abstract][Full Text] [Related]
9. In vitro synergistic activity of clofazimine and other antituberculous drugs against multidrug-resistant Mycobacterium tuberculosis isolates.
Zhang Z; Li T; Qu G; Pang Y; Zhao Y
Int J Antimicrob Agents; 2015 Jan; 45(1):71-5. PubMed ID: 25459737
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of DNF-3 against drug-resistant Mycobacterium tuberculosis.
Islam MI; Han CM; Seo H; Kim S; Mahmud HA; Nam KW; Lee BE; Sadu VS; Lee KI; Song HY
Int J Antimicrob Agents; 2019 Jul; 54(1):69-74. PubMed ID: 30807817
[TBL] [Abstract][Full Text] [Related]
11. In vitro combinatory activity of piperine and anti-tuberculosis drugs in Mycobacterium tuberculosis.
Hegeto LA; Caleffi-Ferracioli KR; Nakamura-Vasconcelos SS; Almeida AL; Baldin VP; Nakamura CV; Siqueira VLD; Scodro RBL; Cardoso RF
Tuberculosis (Edinb); 2018 Jul; 111():35-40. PubMed ID: 30029912
[TBL] [Abstract][Full Text] [Related]
12. In vitro activities of fourteen antimicrobial agents against drug susceptible and resistant clinical isolates of Mycobacterium tuberculosis and comparative intracellular activities against the virulent H37Rv strain in human macrophages.
Rastogi N; Labrousse V; Goh KS
Curr Microbiol; 1996 Sep; 33(3):167-75. PubMed ID: 8672093
[TBL] [Abstract][Full Text] [Related]
13. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis.
Dawson R; Diacon AH; Everitt D; van Niekerk C; Donald PR; Burger DA; Schall R; Spigelman M; Conradie A; Eisenach K; Venter A; Ive P; Page-Shipp L; Variava E; Reither K; Ntinginya NE; Pym A; von Groote-Bidlingmaier F; Mendel CM
Lancet; 2015 May; 385(9979):1738-1747. PubMed ID: 25795076
[TBL] [Abstract][Full Text] [Related]
14. Delamanid Kills Dormant Mycobacteria
Chen X; Hashizume H; Tomishige T; Nakamura I; Matsuba M; Fujiwara M; Kitamoto R; Hanaki E; Ohba Y; Matsumoto M
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28373190
[TBL] [Abstract][Full Text] [Related]
15. SILA-421 activity in vitro against rifampicin-susceptible and rifampicin-resistant Mycobacterium tuberculosis, and in vivo in a murine tuberculosis model.
de Knegt GJ; Bakker-Woudenberg IA; van Soolingen D; Aarnoutse R; Boeree MJ; de Steenwinkel JE
Int J Antimicrob Agents; 2015 Jul; 46(1):66-72. PubMed ID: 25951996
[TBL] [Abstract][Full Text] [Related]
16. In vitro activities of levofloxacin used alone and in combination with first- and second-line antituberculous drugs against Mycobacterium tuberculosis.
Rastogi N; Goh KS; Bryskier A; Devallois A
Antimicrob Agents Chemother; 1996 Jul; 40(7):1610-6. PubMed ID: 8807049
[TBL] [Abstract][Full Text] [Related]
17. Occurrence of disputed rpoB mutations among Mycobacterium tuberculosis isolates phenotypically susceptible to rifampicin in a country with a low incidence of multidrug-resistant tuberculosis.
Al-Mutairi NM; Ahmad S; Mokaddas E; Eldeen HS; Joseph S
BMC Infect Dis; 2019 Jan; 19(1):3. PubMed ID: 30606116
[TBL] [Abstract][Full Text] [Related]
18. Combinatory activity of linezolid and levofloxacin with antituberculosis drugs in Mycobacterium tuberculosis.
Santos NCS; Scodro RBL; de Almeida AL; Baldin VP; Nakamura de Vasconcelos SS; Siqueira VLD; Caleffi-Ferracioli KR; Campanerut-Sá PAZ; Cardoso RF
Tuberculosis (Edinb); 2018 Jul; 111():41-44. PubMed ID: 30029913
[TBL] [Abstract][Full Text] [Related]
19. Combination of amikacin and doxycycline against multidrug-resistant and extensively drug-resistant tuberculosis.
Gonzalo X; Casali N; Broda A; Pardieu C; Drobniewski F
Int J Antimicrob Agents; 2015 Apr; 45(4):406-12. PubMed ID: 25717028
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo antimycobacterial activities of ketone and amide derivatives of quinoxaline 1,4-di-N-oxide.
Villar R; Vicente E; Solano B; Pérez-Silanes S; Aldana I; Maddry JA; Lenaerts AJ; Franzblau SG; Cho SH; Monge A; Goldman RC
J Antimicrob Chemother; 2008 Sep; 62(3):547-54. PubMed ID: 18502817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
